BMO Capital Markets assumed coverage on shares of DexCom Inc. (NASDAQ:DXCM) in a research report report published on Friday morning. The brokerage issued an outperform rating and a $112.00 price objective on the medical device company’s stock.

A number of other brokerages also recently issued reports on DXCM. Jefferies Group reaffirmed a buy rating and set a $98.00 price target on shares of DexCom in a report on Wednesday, August 3rd. Benchmark Co. lowered their target price on DexCom from $106.00 to $86.00 and set a buy rating on the stock in a report on Wednesday, August 3rd. Desjardins raised DexCom from a hold rating to a buy rating in a report on Friday, September 16th. BTIG Research downgraded DexCom from a buy rating to a neutral rating and set a $92.00 target price on the stock. in a report on Wednesday, September 14th. Finally, JPMorgan Chase & Co. reissued a buy rating and issued a $100.00 target price on shares of DexCom in a report on Wednesday, August 3rd. Four research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. DexCom presently has an average rating of Buy and an average price target of $94.96.

DexCom (NASDAQ:DXCM) opened at 92.75 on Friday. DexCom has a 12-month low of $47.92 and a 12-month high of $100.72. The stock’s market cap is $7.78 billion. The firm’s 50-day moving average price is $91.81 and its 200-day moving average price is $75.73.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.12. The business had revenue of $137.30 million for the quarter, compared to the consensus estimate of $132.48 million. DexCom had a negative net margin of 16.42% and a negative return on equity of 19.68%. The company’s revenue for the quarter was up 47.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.05) earnings per share. On average, equities analysts predict that DexCom will post ($0.57) EPS for the current fiscal year.

In other DexCom news, CEO Kevin R. Sayer sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $90.98, for a total transaction of $1,819,600.00. Following the completion of the transaction, the chief executive officer now owns 362,227 shares in the company, valued at approximately $32,955,412.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin R. Sayer sold 7,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $91.79, for a total value of $642,530.00. The disclosure for this sale can be found here. Company insiders own 2.80% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Fund Advisors boosted its position in DexCom by 0.6% in the first quarter. BlackRock Fund Advisors now owns 929,897 shares of the medical device company’s stock valued at $63,149,000 after buying an additional 5,443 shares in the last quarter. BlackRock Group LTD raised its stake in DexCom by 17.6% in the first quarter. BlackRock Group LTD now owns 69,904 shares of the medical device company’s stock valued at $4,747,000 after buying an additional 10,465 shares during the last quarter. BlackRock Inc. raised its stake in DexCom by 314.5% in the first quarter. BlackRock Inc. now owns 9,321 shares of the medical device company’s stock valued at $633,000 after buying an additional 7,072 shares during the last quarter. Franklin Resources Inc. raised its stake in DexCom by 7.7% in the first quarter. Franklin Resources Inc. now owns 1,476,904 shares of the medical device company’s stock valued at $100,296,000 after buying an additional 106,215 shares during the last quarter. Finally, Prudential Financial Inc. raised its stake in DexCom by 37.9% in the first quarter. Prudential Financial Inc. now owns 138,269 shares of the medical device company’s stock valued at $9,390,000 after buying an additional 38,032 shares during the last quarter. Institutional investors and hedge funds own 99.37% of the company’s stock.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

5 Day Chart for NASDAQ:DXCM

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.